-
3 days ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Treatment Approaches (Part 1) For newly diagnosed moderate to severe cGVHD, the panel discussed: Initial steroid dosing: Dr Bishop: 1 mg/kg/day for severe cases, possibly split dosing Dr Shaughnessy: 0.5 mg/kg/day for many cases, 1 mg/kg/day for severe lung or liver involvement All agree on assessing response for at least 1-2 weeks before tapering Steroid taper considerations: Slow, cautious tapers, especially for cGVHD (unlike acute GVHD) Generally 10 mg every 1-2 weeks after stabilization,...
-
3 days ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Clinical Case Presentation (Part 1)A 50-year-old woman underwent allogeneic transplant with reduced-intensity conditioning from a matched unrelated donor for mesenchymal stromal cells. Her donor was a cytomegalovirus-negative 45-year-old man, and GVHD prophylaxis was tacrolimus and mycophenolate mofetil.
-
1 week ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Difficult-to-Diagnose Manifestations The panelists discussed challenging presentations: Pulmonary involvement is often insidious, requiring careful monitoring with serial PFTs Genital/gynecologic involvement is often underdiagnosed but impacts quality of life significantly Neuropathies are difficult to attribute to cGVHD due to multiple potential causes Peripheral edema can make assessment of skin thickening/sclerosis challenging Serositis (inflammation of tissue lining around heart, lungs,...
-
1 week ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Diagnosis and Clinical ChallengesFor diagnosis, the panel generally relies on clinical features rather than biopsies for typical presentations.
-
2 weeks ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Overview and Pathophysiology of cGVHDThe panel featured Dr Catherine Lee (Fred Hutch Cancer Center), Dr Michael Bishop (University of Chicago), and Dr Paul Shaughnessy (Sarah Cannon Transplant cellular therapy program).
-
2 weeks ago | 
targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy
Clinical Prevalence and Risk Factors The panel discussed the frequency of cGVHD in clinical practice: Common risk factors include HLA disparity, donor characteristics, and GVHD prophylaxis regimen Post-transplant cyclophosphamide has reduced overall incidence of cGVHD, though severity remains similar when it does occur The panel still quotes patients approximately 50% risk of developing cGVHD Most common manifestations in practice are: Eyes, mouth, and skin (consensus among all panelists)...
-
Aug 9, 2024 | 
brainandlife.org | Catherine Lee
My mother looks like Frankenstein's monster. That's the thought that ran through my mind as I looked at her in the hospital. Her thick black hair had been shaved, and I could see the stitches where neurosurgeons had removed part of her skull. They had opened her up twice already because her tumor, a glioblastoma—the most aggressive form of brain cancer—kept growing back. Her doctors recommended further experimental treatment, which would have subjected her to yet more surgery. She declined.
-
Apr 12, 2024 | 
newsbreak.com | Catherine Lee
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
-
Apr 12, 2024 | 
newsbreak.com | Catherine Lee
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
-
Mar 7, 2024 | 
ajmc.com | Joan C. Lo |Malini Chandra |Wei Yang |Nailah Thompson |Catherine Lee |Mohan Ramaswamy | +2 more
ABSTRACTObjectives: Bone mineral density (BMD) and fracture risk calculators (eg, the Fracture Risk Assessment Tool [FRAX]) guide primary prevention care in postmenopausal women. BMD scores use non-Hispanic White (NHW) reference data for T-score classification, whereas FRAX incorporates BMD, clinical risk factors, and population differences when calculating risk. This study compares findings among Asian, Black, and NHW women who underwent osteoporosis screening in a US health care system.
